Status:
UNKNOWN
Feasibility of Identifying, Enrolling and Following Acute and Early HIV-1 Infected Individuals.
Lead Sponsor:
MRC/UVRI and LSHTM Uganda Research Unit
Collaborating Sponsors:
International AIDS Vaccine Initiative
Conditions:
Acute Human Immunodeficiency Virus Type I Infection
Eligibility:
All Genders
18+ years
Brief Summary
It is only between peak viremia and viral setpoint in natural acute HIV-1 infection that the immune response overwhelms viral replication resulting in a plasma viral load decline. The aim will be to c...
Eligibility Criteria
Inclusion
- Females and males.
- Able and willing to provide informed consent.
- Willing to undergo HIV testing using GeneX pert Viral Load assay.
- Able and willing to provide accurate locator information for tracking purposes and willing to be contacted by study staff.
- Willing to complete interviewer administered questionnaires on risk factors and if infected, questions related to the route and timing of exposure.
Exclusion
- Has any condition that in the opinion of the principal investigator or designee, would preclude provision of informed consent, or otherwise interfere with achieving the study objectives.
- Participation in a current clinical trial unless approved by the investigators and IAVI medical monitor.
Key Trial Info
Start Date :
February 17 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05372510
Start Date
February 17 2021
End Date
December 31 2022
Last Update
May 12 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
MRC/UVRI & LSHTM, Uganda Research Unit,Masaka station
Masaka, Uganda